CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog & Media
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Media Room

Explore our latest press releases, announcements, and updates on groundbreaking immunotherapy research.

For media inquiries, please contact us at [email protected].

  • Media Room Article

    Cancer Research Institute and RevImmune Announce Dosing of First Patient in New Phase 2 Study Assessing Therapeutic Benefit of Interleukin-7 in Patients with Cancer and COVID-19

    First study to test RevImmune’s IL-7 drug candidate in cancer patients infected with the SARS-CoV-2 coronavirus at…

    March 30, 2021
  • Media Room Article

    El Cancer Research Institute y RevImmune anuncian la administración de la primera dosis a un paciente del nuevo estudio de fase II en el que se evalúan las ventajas terapéuticas de la interleucina-7 en pacientes con cáncer y COVID-19

    Primer estudio en probar la IL-7 de RevImmune, un fármaco de interés médico, en pacientes con cáncer…

    March 30, 2021
  • Media Room Article

    Combination Drug Strategies Gain Ground in Global Immuno-Oncology Pipeline of PD-1 and PD-L1 Clinical Trials, New Report from Cancer Research Institute Reveals

    Combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials, new report…

    November 11, 2020
  • Media Room Article

    Cancer Research Institute CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey Receives Inaugural Tara Withington Public Service Award from the Society for Immunotherapy of Cancer

    Cancer Research Institute CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey receives inaugural Tara Withington Public…

    November 11, 2020
  • Media Room Article

    La Directora Ejecutiva y Directora de Asuntos Científicos del CRI, Dra. Jill O’Donnell-Tormey, recibe el premio inaugural Tara Withington Public Service de la Sociedad para la Inmunoterapia del Cáncer (SITC)

    La Directora Ejecutiva y Directora de Asuntos Científicos del CRI, Dra. Jill O’Donnell-Tormey, recibe el premio inaugural…

    November 11, 2020
  • Media Room Article

    La combinación de fármacos gana terreno en el desarrollo de la inmunooncología de los ensayos clínicos con inhibidores de PD-1 y PD-L1, según un nuevo informe del Cancer Research Institute

    La combinación de fármacos gana terreno en el desarrollo de la inmunooncología en ensayos clínicos con inhibidores…

    November 11, 2020
  • Media Room Article

    An Initiative Led by Parker Institute for Cancer Immunotherapy and Cancer Research Institute Discovers Keys That Could Unlock Better Personalized Treatments to Destroy Cancer

    International neoantigen initiative Tumor Neoantigen Selection Alliance (TESLA) identifies parameters for cancer vaccine or cell therapy advancement

    October 9, 2020
  • Media Room Article

    Iniciativa encabezada por el Parker Institute for Cancer Immunotherapy y el Cancer Research Institute descubre las claves que podrían revelar mejores tratamientos personalizados contra el cáncer

    La Iniciativa internacional Alianza para la Selección de Neoantígenos Tumorales (TESLA, por sus siglas en inglés) identifica…

    October 9, 2020
  • Media Room Article

    Immunotherapy Drug Development Pipeline Continues Significant Growth In 2020 Despite Global Pandemic Impact

    Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.

    September 18, 2020
Previous Page
1 … 5 6 7 8 9 … 21
Next Page
Father and son

Join CRI in Shaping the Future of Immunotherapy

Support the pioneering work of CRI in advancing immunotherapy.

See ways to give
CRI Logo

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog & Media
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute